Dutch Growth Research Foundation, Rotterdam, The Netherlands.
Clin Endocrinol (Oxf). 2010 Aug;73(2):212-9. doi: 10.1111/j.1365-2265.2010.03789.x. Epub 2010 Jan 23.
Untreated girls with Turner syndrome (TS) have short stature, relatively broad shoulders, a broad pelvis, short legs, a high fat mass and low muscle mass. Our objective was to assess the effect of the weak androgen oxandrolone (Ox) on body proportions and composition in growth hormone (GH)-treated girls with TS.
DESIGN/PATIENTS: 133 patients were included in a randomized, placebo-controlled, double-blind study.
Patients were treated with GH (1.33 mg/m(2) per day) from baseline, combined with placebo (Pl) or Ox in a low (0.03 mg/kg per day) or previously conventional (0.06 mg/kg per day) dose from the age of eight, and oestrogens from the age of twelve. Sitting height, biacromial and biiliacal distances compared with height (i.e. shape values), BMI, waist circumference, sum of 4 skinfolds (sum4skin) and upper arm muscle area (UAMA) SD scores (SDS) were assessed half-yearly.
Compared with GH + Pl, adult shape values on GH + Ox tended to be higher for sitting height (Ox 0.03, P = 0.2; Ox 0.06, P = 0.02) and biacromial distance (Ox 0.03, P = 0.2; Ox 0.06, P = 0.07) and lower for biiliacal distance (Ox 0.03, P = 0.004; Ox 0.06, P = 0.08). Sum4skin SDS tended to decrease more (Ox 0.03, P = 0.2; Ox 0.06, P = 0.005) while UAMA SDS increased more (Ox 0.03, P < 0.001; Ox 0.06, P < 0.001) than on GH + Pl. The increase in BMI and waist circumference SDS was comparable between the dosage groups.
In GH-treated girls with TS, Ox 0.06 increases sitting height and tends to increase biacromial distance and decrease biiliacal distance, while Ox 0.03 significantly decreases biiliacal distance compared with height. Furthermore, Ox 0.06 reduces subcutaneous fat mass, and both Ox dosages increase muscle mass.
未经治疗的特纳综合征(TS)女孩身材矮小,肩部较宽,骨盆较宽,下肢较短,体脂较高,肌肉量较低。我们的目的是评估弱雄激素氧雄龙(Ox)对 GH 治疗的 TS 女孩的身体比例和组成的影响。
设计/患者:133 名患者纳入一项随机、安慰剂对照、双盲研究。
患者从基线开始每天接受 GH(1.33mg/m2)治疗,同时每天接受低剂量(0.03mg/kg)或之前常规剂量(0.06mg/kg)的安慰剂(Pl)或 Ox,从 12 岁开始接受雌激素治疗。每半年评估一次坐高、双肩胛骨和双髂嵴距离与身高的比值(即体型值)、BMI、腰围、4 个皮褶厚度之和(sum4skin)和上臂肌肉区(UAMA)SD 评分(SDS)。
与 GH+Pl 相比,GH+Ox 组成年体型值的坐高(Ox0.03,P=0.2;Ox0.06,P=0.02)和双肩胛骨距离(Ox0.03,P=0.2;Ox0.06,P=0.07)呈升高趋势,双髂嵴距离(Ox0.03,P=0.004;Ox0.06,P=0.08)呈降低趋势。Sum4skinSDS 呈下降趋势(Ox0.03,P=0.2;Ox0.06,P=0.005),而 UAMA SDS 呈上升趋势(Ox0.03,P<0.001;Ox0.06,P<0.001),大于 GH+Pl 组。BMI 和腰围 SDS 的增加在两个剂量组之间相似。
在 GH 治疗的 TS 女孩中,Ox0.06 增加坐高,倾向于增加双肩胛骨距离,降低双髂嵴距离,而 Ox0.03 与身高相比显著降低双髂嵴距离。此外,Ox0.06 减少皮下脂肪量,两种 Ox 剂量均增加肌肉量。